Skip to Main Content

Paper Details

Bruton tyrosine kinase degradation as a therapeutic strategy for cancer.
Blood
102
2019
B-cell, B-cell lymphomas, B-cell malignancies, BTK, Bruton tyrosine kinase, C481S, C481S-BTK, C481S-BTK mutation, DD-03-171, IKFZ1, IKFZ3, MCL, cancer, cancer cells, ibrutinib, mantle, mantle cell lymphoma (MCL) cells, patient, patient-derived xenografts, tyrosine
Author NameAffiliation
Tyler B FaustDana-Farber Cancer Institute
Tyler B FaustHarvard Medical School
David M Weinstock
David M WeinstockBroad Institute of Harvard and Massachusetts Institute of Technology
Nathanael S GrayDana-Farber Cancer Institute
Nathanael S GrayHarvard Medical School
Nathanael S GrayDana-Farber Cancer Institute
Nathanael S GrayHarvard Medical School
  • 1 - 8

Datasets

Release 1.2